GlassScriptPhysician profile
Lewis Kanengiser
NPI 1124120787
$2,076.68
in general payments reported to CMS, 2019-2025
20 companies · $515 in 2025
The $515 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $398 · 2020: $240 · 2021: $162 · 2022: $215 · 2023: $232 · 2024: $315 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,062.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,061.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $576.26 | 2019-2025 | Evenity |
| Abbvie INC. | $507.42 | 2019-2025 | |
| Gilead Sciences, INC. | $153.34 | 2024-2025 | Descovy |
| Novartis Pharmaceuticals Corporation | $140.14 | 2022-2025 | |
| Lilly USA, LLC | $93.44 | 2023-2025 | Mounjaro, Kisunla, Zepbound |
| Glaxosmithkline, LLC. | $86.48 | 2019-2023 | Arexvy, Shingrix |
| Pfizer INC. | $83.04 | 2023-2025 | |
| Sanofi Pasteur INC. | $59.37 | 2022-2023 | |
| Phathom Pharmaceuticals, INC. | $54.33 | 2025 | Voquezna |
| Sumitomo Pharma America, INC. | $48.11 | 2025 | Gemtesa |
| Electromed, INC. | $39.68 | 2024-2025 | Smartvest |
| Arbor Pharmaceuticals, INC. | $37.55 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $33.22 | 2025 | |
| Viiv Healthcare Company | $30.85 | 2024 | Apretude |
| Kowa Pharmaceuticals America, INC. | $30.83 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $28.31 | 2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $24.47 | 2025 | Wegovy |
| Amarin Pharma, INC. | $21.77 | 2020 | |
| Ibsa Pharma INC. | $14.18 | 2025 | Tirosint, Licart, Flector |
| E.R. Squibb & Sons, L.L.C. | $13.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lewis Kanengiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.